A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Completed · Phase 2
Conditions studied: Kidney Transplantation
In brief
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Key facts
- Study ID
- NCT00106639
- Run by
- Pfizer
- People needed
- 61
- Starts
- 2005-05-01
- Expected to finish
- 2006-07-01
- Last updated by the study team
- 2013-03-12
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
You may not qualify if…
- Recipient of any non-kidney transplant
Where it is running
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Palo Alto, California, United States
- Pfizer Investigational Site — San Diego, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — Stanford, California, United States
- Pfizer Investigational Site — Denver, Colorado, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — New Orleans, Louisiana, United States
- Pfizer Investigational Site — St Louis, Missouri, United States
- Pfizer Investigational Site — St Louis, Missouri, United States
- Pfizer Investigational Site — Livingston, New Jersey, United States
- Pfizer Investigational Site — New York, New York, United States
- Pfizer Investigational Site — New York, New York, United States
- Pfizer Investigational Site — Portland, Oregon, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — Richmond, Virginia, United States
- Pfizer Investigational Site — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.